PMID- 38343834
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240216
DP  - 2024 Jan 23
TI  - Implementing a Metabolism-Informed Approach for Smoking Cessation in an Alaska 
      Tribal Health System: Study Protocol for a Single-Arm Implementation Pilot Trial.
LID - rs.3.rs-3874126 [pii]
LID - 10.21203/rs.3.rs-3874126/v1 [doi]
AB  - BACKGROUND: Individualized treatment for commercial tobacco smoking cessation, 
      such as through the utilization of the nicotine metabolite ratio (NMR), offers 
      substantial clinical benefit. NMR is a metabolism-informed biomarker that can be 
      used to guide medication selection. NMR testing is particularly promising for 
      tobacco cessation efforts in populations with high rates of smoking, such as some 
      Alaska Native and American Indian (AN/AI) communities. To date, no prior study 
      has evaluated the implementation of NMR-guided tobacco cessation with AN/AI 
      populations. METHODS: The present "QUIT" protocol is a two-phase study that will 
      occur at Southcentral Foundation (SCF), an Alaska Native-owned health system, 
      serving 70,000 AN/AI people, based in Anchorage, Alaska. In Phase one, 
      qualitative interviews with customer-owners (patients), providers and 
      administrators (n = 36) and a 10-participant beta-test will be used to refine a 
      strategy to implement NMR testing in the health system. Phase two will involve a 
      single-arm pilot trial (n = 50) and qualitative interviews throughout data 
      collection (n = 48) to evaluate the implementation strategy and explore the 
      real-world acceptability and feasibility of NMR testing to guide tobacco 
      cessation with AN/AI populations. DISCUSSION: This study utilizes a 
      community-based participatory approach to refine and implement a nicotine 
      metabolism-informed smoking cessation program in a Tribal healthcare setting. The 
      process and findings from this study will reflect the importance of 
      customer-owner choice and honor the lived experience involved in quitting 
      commercial tobacco. Pilot study data will inform the effect and sample sizes 
      required for a future pragmatic trial of NMR-guided smoking cessation.
FAU - Jansen, Kelley
AU  - Jansen K
AD  - Southcentral Foundation.
FAU - Tranby, Brianna
AU  - Tranby B
AD  - Mayo Clinic.
FAU - Shane, Aliassa
AU  - Shane A
AD  - Southcentral Foundation.
FAU - Takeno, Todd
AU  - Takeno T
AD  - Southcentral Foundation.
FAU - Chadwick, Kelly
AU  - Chadwick K
AD  - University of Washington.
FAU - Sinicrope, Pamela
AU  - Sinicrope P
AD  - Mayo Clinic.
FAU - Shaw, Jennifer
AU  - Shaw J
AD  - University of Alaska Fairbanks.
FAU - Tyndale, Rachel
AU  - Tyndale R
AD  - University of Toronto.
FAU - Harris, Jeffrey
AU  - Harris J
AD  - University of Washington.
FAU - Patten, Christi
AU  - Patten C
AD  - Mayo Clinic.
FAU - Avey, Jaedon
AU  - Avey J
AD  - Southcentral Foundation.
LA  - eng
GR  - S06 GM142122/GM/NIGMS NIH HHS/United States
PT  - Preprint
DEP - 20240123
PL  - United States
TA  - Res Sq
JT  - Research square
JID - 101768035
PMC - PMC10854299
OTO - NOTNLM
OT  - Alaska Native and American Indian
OT  - Health Services
OT  - Implementation
OT  - Nicotine Metabolite Ratio
OT  - Tobacco Cessation
COIS- Competing Interests: None to declare.
EDAT- 2024/02/12 15:42
MHDA- 2024/02/12 15:43
PMCR- 2024/02/09
CRDT- 2024/02/12 04:12
PHST- 2024/02/12 15:42 [pubmed]
PHST- 2024/02/12 15:43 [medline]
PHST- 2024/02/12 04:12 [entrez]
PHST- 2024/02/09 00:00 [pmc-release]
AID - rs.3.rs-3874126 [pii]
AID - 10.21203/rs.3.rs-3874126/v1 [doi]
PST - epublish
SO  - Res Sq [Preprint]. 2024 Jan 23:rs.3.rs-3874126. doi: 10.21203/rs.3.rs-3874126/v1.